The Immutep (ASX:IMM) share price is up 25% in a month and could go higher

This biotech company's shares have been on fire…

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immutep Ltd (ASX: IMM) share price is pushing higher again on Monday despite the market decline.

At the time of writing, the biotechnology company's shares are up almost 4% to 55 cents.

This means the Immutep share price is now up 25% in the space of a month.

Why is the Immutep share price charging higher this month?

Investors have been bidding the Immutep share price higher in recent weeks following a series of positive updates.

One of those was the announcement of the grant of a patent in China in late August. This patent relates to LAG525, which is a humanised form of Immutep's IMP701 antibody which is out-licensed to Novartis.

The company followed this up a few days later with another announcement relating to its Chinese operations. The release explains that its Chinese partner for eftilagimod alpha (efti), EOC Pharma, is planning to expand its clinical trial pipeline.

EOC Pharma is preparing to initiate a clinical trial of efti in combination with an anti-PD-1 therapy. The new trial builds on the latest promising data presented by Immutep at ASCO 2021 and on previously announced Phase II trial evaluating efti in combination with chemotherapy in metastatic breast cancer patients.

And then finally, earlier this month the company revealed that the last patient has been enrolled and safely dosed in its Stage 2 of Part B of its Phase II TACTI-002 study.

This study is being conducted in collaboration with Merck & Co. It is evaluating the combination of efti with Merck's Keytruda product in up to 183 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

Immutep expects to report further data from TACTI-002 at a scientific conference in calendar year 2021 or early calendar year 2022.

Are its shares good value?

Despite the strong gain by the Immutep share price over the last few weeks, one leading broker believes it could still go higher.

According to a recent note out of Bell Potter, its analysts have a speculative buy rating and $1.00 price target on the company's shares.

Based on the current Immutep share price, this implies potential upside of 82% over the next 12 months.

It commented: "We retain Buy (spec). Our hypothetical M&A valuation for IMM is revised to $1.48/sh, which helps ground our DCF valuation. IMM remains one of our key picks in the biotech space for FY22."

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Share Gainers

Why Bubs, Chrysos, JB Hi-Fi, and Paladin Energy shares are storming higher today

These shares are having a good time on hump day. But why?

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Share Gainers

Why HMC, Hub24, Liontown, and Yancoal shares are racing higher today

These shares are having a good session. What's driving them higher?

Read more »

Share Gainers

Why Canyon Resources, Ioneer, Iress, and Predictive Discovery shares are pushing higher

These shares are starting the week on a positive note. But why?

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Share Gainers

Why Insignia, Lovisa, Megaport, and Telix shares are charging higher today

These shares are ending the week on a positive note. Let's find out why.

Read more »

A happy girl in a yellow playsuit with a zip gives the thumbs up
Share Gainers

Why is the Zip share price rocketing 7% today?

Exciting news from the US could be the catalyst for investor buying now.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Arafura, Genesis Minerals, Life360, and Premier Investments shares are shooting higher

These shares are climbing more than most on Thursday. But why?

Read more »

man looking happy and excited as he looks at his mobile phone
Share Gainers

Why Arafura, Baby Bunting, Guzman y Gomez, and PWR shares are storming higher

These shares are having a good time on hump day. Let's find out why...

Read more »

an elderly woman wearing boxing gloves raises one toward her face in a boxing pose while looking towards the camera with grey hair and spectacles on.
Retail Shares

Why this beaten-down ASX share just rocketed 20%

Investors are sending this ASX small cap flying higher on Tuesday. But why?

Read more »